NEEDHAM, Mass., Sept. 06, 2017 -- Allegations have surfaced that H&R Block’s (HRB Tax Group, Inc.) tax division has been selling customers its Peace of Mind® (POM) Extended Services Plan, and then failing to professionally represent those customers during an IRS audit, or reimburse them for the audit, or any IRS demand or penalty, according to the POM provisions. The attorneys from Goldman & Pease, LLC would like to speak with any Massachusetts residents who bought H&R Block’s Peace of Mind® Plan, and then were not professionally represented by H&R Block during the course of the audit, or reimbursed by H&R Block for the audit. The lawyers at Goldman & Pease LLC are experienced litigators, who are working hard to investigate this matter and provide counsel and representation to numerous individuals throughout Massachusetts. For more information, please visit us at http://www.goldmanpease.com and contact us at [email protected].
.


Italy Fines Apple €98.6 Million Over App Store Dominance
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 



